Show an ad over header. AMP

I am the FIRST

Exclusive poll: Americans don't want to share a COVID vaccine with other countries

Data: The Harris Poll; Chart: Andrew Witherspoon/Axios

If the U.S. is the first country to develop a coronavirus vaccine, most Americans don't want to share it right away with the rest of the world — but they're OK putting high-risk people at the front of the line within the U.S., according to a new Harris poll shared exclusively with Axios.

Why it matters: Whenever the first vaccine comes, there won't be enough to go around. Experts say both of those tiers of rationing — divvying up the available doses internationally, and then a risk-based system to decide who gets it first within each country — will be necessary.


Where it stands: Dozens of potential vaccines are under development. No product has yet been proven to work, and it’s entirely possible that even the apparent front-runners may not pan out.

  • It’s premature to assume that a vaccine is right around the corner, or that the first successful one would be a knockout punch whenever it does arrive.
  • But the drumbeat of encouraging news has been steady enough that it’s reasonable to start thinking about how to distribute that first drug, whenever it does arrive.

By the numbers: 69% of respondents in the Harris survey said they’d support a priority system for distributing a vaccine within the U.S., while just 31% said they’d prefer a first-come, first-served approach.

  • Support for a priority system was consistently high among men and women, Republicans and Democrats and all income levels.
  • 73% said health care workers should get priority access to a vaccine once there is one, followed by seniors (71%), people with compromised immune systems (68%) and essential workers (60%).

Between the lines: This sort of structured, risk-based allocation would be a lot different from what most Americans are used to, in a health care system that typically allocates resources based on patients' ability to pay.

  • If people are already getting comfortable with the idea of waiting in line before getting access to a vaccine, that could help make this high-stakes, highly complex process work.

Yes, but: Although most Americans are on board with a priority system domestically, they’re not wild about the same kind of risk-based allocation internationally.

  • 66% of Americans said that if the U.S. develops the vaccine, it should only be made available abroad after all U.S. orders have been filled; just 34% said it should be made available overseas immediately.

Three countries are at the front of the pack in the vaccine race: The U.S., China and the U.K. No matter who gets there first, they won’t have enough available to vaccinate their entire populations, or anywhere close to it.

  • Experts say the “winning” country will likely have some advantage when it comes time to distribute the available doses, but if any one country is able to hoard them all, the global pandemic could rage on for years.

Americans are more skeptical of foreign-developed vaccines: Overall, 69% said they are at least somewhat likely to take a COVID-19 vaccine as soon as it’s available. But asked whether they’d use a vaccine developed by another country, that number slipped to 51%.

Methodology: The Harris survey was conducted Aug. 14-16 among a representative sample of 1,967 American adults.

Why the startup world needs to ditch "unicorns" for "dragons"

When Aileen Lee originally coined the term "unicorn" in late 2013, she was describing the 39 "U.S.-based software companies started since 2003 and valued at over $1 billion by public or private market investors."

Flashback: It got redefined in early 2015 by yours truly and Erin Griffith, in a cover story for Fortune, as any privately-held startup valued at $1 billion or more. At the time, we counted 80 of them.

Keep reading... Show less

Scoop: Facebook's new moves to lower News Feed's political volume

Facebook plans to announce that it will de-emphasize political posts and current events content in the News Feed based on negative user feedback, Axios has learned. It also plans to expand tests to limit the amount of political content that people see in their News Feeds to more countries outside of the U.S.

Why it matters: The changes could reduce traffic to some news publishers, particularly companies that post a lot of political content.

Keep reading... Show less

Scoop: Amazon quietly getting into live audio business

Amazon is investing heavily in a new live audio feature that's similar to other live audio offerings like Clubhouse, Twitter Spaces and Spotify's new live audio platform, sources tell Axios.

Why it matters: As with Amazon's efforts in podcasting and music subscriptions, the company sees live audio as a way to bolster the types of content it can offer through its voice assistant, Alexa, and its smart speaker products.

Keep reading... Show less

Hurricane Ida exposes America's precarious energy infrastructure

The powerful hurricane that plunged New Orleans into darkness for what could be weeks is the latest sign that U.S. power systems are not ready for a warmer, more volatile world.

The big picture: “Our current infrastructure is not adequate when it comes to these kinds of weather extremes,” Joshua Rhodes, a University of Texas energy expert, tells Axios.

Keep reading... Show less

"We must go further": 70% of adults in European Union are fully vaccinated

About 70% of adults in the European Union are fully vaccinated against COVID-19, Ursula von der Leyen, the president of the European Commission, said Tuesday.

Why it matters: The milestone makes the E.U. one of the world's leaders in inoculations, after an initially lagging vaccine campaign, the New York Times notes.

Keep reading... Show less

What Elizabeth Holmes jurors will be asked ahead of fraud trial

Jury selection begins today in USA v. Elizabeth Holmes, with the actual jury trial to get underway on Sept. 8.

Why it matters: Theranos was the biggest fraud in Silicon Valley history, putting both hundreds of millions of dollars and thousands of patients' health at risk.

Keep reading... Show less

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories